Search Result

Results for "

FGFR-1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	FGFR (193) AAK1 (1) Akt (5) AMPK (2) Anaplastic lymphoma kinase (ALK) (1) Apoptosis (23) Aurora Kinase (3) Autophagy (21) Bcr-Abl (7) Biochemical Assay Reagents (1) c-Fms (10) c-Kit (24) c-Met/HGFR (3) c-Myc (1) Caspase (1) CDK (4) Cytochrome P450 (1) Discoidin Domain Receptor (1) DNA/RNA Synthesis (1) Drug Intermediate (1) Drug Metabolite (3) EGFR (6) Endogenous Metabolite (5) Ephrin Receptor (1) Epigenetic Reader Domain (1) ERK (6) Ferroptosis (1) FLT3 (10) HDAC (1) IFNAR (1) IGF-1R (1) Insulin Receptor (1) Interleukin Related (1) IRAK (1) Isotope-Labeled Compounds (9) Itk (1) JAK (1) JNK (1) LIM Kinase (LIMK) (1) MAP3K (1) MAP4K (1) MELK (1) Mitosis (1) mRNA (1) Necroptosis (2) NOD-like Receptor (NLR) (1) Nucleoside Antimetabolite/Analog (2) p38 MAPK (3) PARP (1) PD-1/PD-L1 (1) PDGFR (60) Peptide-Drug Conjugates (PDCs) (1) PERK (2) PI3K (1) PROTAC Linkers (1) PROTACs (4) Pyroptosis (2) Raf (3) Reactive Oxygen Species (ROS) (4) Reference Standards (35) RET (10) Ribosomal S6 Kinase (RSK) (1) ROS Kinase (1) Small Interfering RNA (siRNA) (4) Src (16) STAT (1) Syk (1) TGF-beta/Smad (1) Trk Receptor (2) ULK (1) VEGFR (79) Wee1 (1)
By Research Areas:	Cancer (198) Cardiovascular Disease (5) Infection (3) Inflammation/Immunology (14) Metabolic Disease (5) Neurological Disease (10)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) mRNA (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (2) siRNAs (4)

220

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

GMP Molecules

Targets Recommended: FGFR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10981

Lenvatinib Maximum Cited Publications 92 Publications Verification E7080	VEGFR FGFR PDGFR c-Kit RET	Cancer
Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits *VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET*, shows potent antitumor activities ^[1] .

HY-18708

Erdafitinib 35+ Cited Publications JNJ-42756493	FGFR Apoptosis	Cancer
Erdafitinib (JNJ-42756493) is a potent and orally available *FGFR* family inhibitor; inhibits FGFR1/2/3/4 with IC₅₀s of 1.2, 2.5, 3.0 and 5.7 nM, respectively.

HY-13311

Infigratinib 45+ Cited Publications BGJ-398; NVP-BGJ398	FGFR Apoptosis	Cancer
Infigratinib (BGJ-398; NVP-BGJ398) is a potent inhibitor of the *FGFR* family with IC₅₀s of 0.9 nM, 1.4 nM, 1 nM, and 60 nM for *FGFR1, FGFR2, FGFR3, and FGFR4*, respectively.

HY-12047

Ponatinib 45+ Cited Publications AP24534	Bcr-Abl PDGFR VEGFR FGFR Src Autophagy	Cancer
Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with IC₅₀s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, *FGFR1, and Src*, respectively ^[1].

HY-N0060

Ferulic acid Maximum Cited Publications 16 Publications Verification Coniferic acid	FGFR Endogenous Metabolite	Infection Neurological Disease Cancer
Ferulic acid is a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor with IC₅₀s of 3.78 and 12.5 μM for *FGFR1* and *FGFR2*, respectively.

HY-10208

Pazopanib 20+ Cited Publications GW786034	VEGFR c-Kit PDGFR Autophagy FGFR	Cancer
Pazopanib (GW786034) is a novel multi-target inhibitor of *VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms* with IC₅₀s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.

HY-109099

Pemigatinib 20+ Cited Publications INCB054828	FGFR	Cancer
Pemigatinib (INCB054828) is an orally active, selective *FGFR* inhibitor with IC₅₀s of 0.4 nM, 0.5 nM, 1.2 nM, 30 nM for FGFR1, FGFR2, FGFR3, FGFR4, respectively. Pemigatinib has the potential for cholangiocarcinoma ^[1] .

HY-13330

Fexagratinib 30+ Cited Publications AZD4547; ADSK091	FGFR	Cancer
Fexagratinib (AZD4547; ADSK091) is a potent inhibitor of the *FGFR* family with IC₅₀s of 0.2 nM, 2.5 nM, 1.8 nM, and 165 nM for *FGFR1, FGFR2, FGFR3, and FGFR4*, respectively.

HY-10321

PD173074 20+ Cited Publications	FGFR VEGFR Apoptosis	Cancer
PD173074 is a potent *FGFR1* inhibitor with an IC₅₀ of 25 nM and also inhibits VEGFR2 with an IC₅₀ of 100-200 nM, showing 1000-fold selectivity for FGFR1 over PDGFR and c-Src.

HY-10407

SU 5402 10+ Cited Publications	VEGFR FGFR PDGFR	Cancer
SU 5402 is a potent multi-targeted receptor tyrosine kinase inhibitor with IC₅₀ of 20 nM, 30 nM, and 510 nM for VEGFR2, *FGFR1, and PDGFRβ*, respectively.

HY-12297

Sulfatinib 2 Publications Verification Surufatinib; HMPL-012	FGFR VEGFR	Cancer
Sulfatinib (Surufatinib) is a potent and highly selective tyrosine kinase inhibitor against *VEGFR1/2/3, FGFR1* and *CSF1R* with IC₅₀s of in a range of 1 to 24 nM.

HY-P5321

bFGF (119-126) 5 Publications Verification	FGFR	Cancer
bFGF (119-126) is a ligand of bFGF. The complex formed by bFGF (119-126) and bFGF can bind to *FGFR1, while inhibiting the bFGF-FGFR1* interaction, FGFR1 phosphorylation and downstream signaling pathways. Therefore, bFGF (119-126) induces cell apoptosis and inhibits cell proliferation, migration, angiogenesis and metastasis. When conjugated with a carrier, bFGF (119-126) enhances cellular uptake via FGFR-mediated endocytosis and serves as an effective *FGFR*-targeted ligand. When used in combination with ultrasound and Doxorubicin (HY-15142A), bFGF (119-126) significantly enhances the inhibitory effect on tumors. bFGF (119-126) is applicable to research related to lung cancer, breast cancer, glioblastoma and ovarian cancer ^[1] .

HY-13304

LY2874455 3 Publications Verification	FGFR	Cancer
LY2874455 is a *pan-FGFR* inhibitor with IC₅₀s of 2.8, 2.6, 6.4, 6 nM for *FGFR1, FGFR2, FGFR3, FGFR4*, respectively.

HY-10981A

Lenvatinib mesylate Maximum Cited Publications 92 Publications Verification E7080 mesylate	VEGFR FGFR PDGFR RET c-Kit	Cancer
Lenvatinib mesylate (E7080 mesylate), an oral, multi-targeted tyrosine kinase inhibitor that inhibits *VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET*, shows potent antitumor activities ^[1] .

HY-101296

PD-166866 10+ Cited Publications	FGFR Autophagy	Cancer
PD166866 is a selective *FGFR1* tyrosine kinase inhibitor with an IC₅₀ of 52.4 nM.

HY-101466

E7090	FGFR	Cancer
E7090 is an orally available, potent, and selective *FGFR* inhibitor with IC₅₀s of 0.71 nM, 0.50 nM, 1.2 nM, and 120 nM for *FGFR1/FGFR2/FGFR3/FGFR4*, respectively ^[1].

HY-16025

EOC317 1 Publications Verification ACTB-1003	FGFR VEGFR	Cancer
EOC317 (ACTB-1003) is an oral kinase inhibitor with IC₅₀s of 6, 2 and 4 nM for *FGFR1, VEGFR2* and Tie-2.

HY-12009

Pazopanib Hydrochloride 20+ Cited Publications GW786034 Hydrochloride	PDGFR VEGFR FGFR c-Kit c-Fms Autophagy	Cancer
Pazopanib Hydrochloride (GW786034 Hydrochloride) is a novel multi-target inhibitor of *VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms* with an IC₅₀ of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.

HY-19957

Zoligratinib 3 Publications Verification Debio 1347; CH5183284	FGFR	Cancer
Zoligratinib (Debio 1347) is an orally available and selective *FGFR* inhibitor with IC₅₀s of 9.3, 7.6, and 22 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively.

HY-10517

Orantinib 5+ Cited Publications SU6668; TSU-68	PDGFR FGFR VEGFR Apoptosis	Cancer
Orantinib (SU6668; TSU-68) is a multi-targeted receptor tyrosine kinase inhibitor with K_is of 2.1 μM, 8 nM and 1.2 μM for *Flt-1, PDGFRβ* and *FGFR1*, respectively.

HY-N0060A

Ferulic acid sodium Maximum Cited Publications 16 Publications Verification Coniferic acid sodium	FGFR Endogenous Metabolite Reactive Oxygen Species (ROS)	Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
Ferulic acid sodium is a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor with IC₅₀s of 3.78 and 12.5 μM for *FGFR1* and *FGFR2*, respectively.

HY-18602

FIIN-2	FGFR	Cancer
FIIN-2 is an irreversible inhibitor of *FGFR* with an IC₅₀ of 3.1, 4.3, 27, and 45 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively.

HY-N0060R

Ferulic acid (Standard) 1 Publications Verification Coniferic acid (Standard)	Reference Standards FGFR Endogenous Metabolite	Cancer
Ferulic acid (Standard) is the analytical standard of Ferulic acid. This product is intended for research and analytical applications. Ferulic acid is a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor with IC50s of 3.78 and 12.5 μM for FGFR1 and FGFR2, respectively.

HY-101768

PRN1371 1 Publications Verification	FGFR c-Fms	Cancer
PRN1371 is a highly selective and potent *FGFR1-4* and *CSF1R* inhibitor with IC₅₀s of 0.6, 1.3, 4.1, 19.3 and 8.1 nM for FGFR1, FGFR2, FGFR3, FGFR4 and CSF1R, respectively ^[1].

HY-165298

DGY-09-192	PROTACs FGFR ERK	Cancer
DGY-09-192 is a PROTAC *FGFR1/2* degrader (FGFR1: DC₅₀ = 4.35 nM; FGFR2: DC₅₀ = 70 nM). DGY-09-192 preferentially degrades wild-type *FGFR1/2* and multiple *FGFR2* fusion proteins (including *FGFR2*-PHGDH and *FGFR2*-OPTN). DGY-09-192 suppresses downstream *FGFR* signaling (reducing phosphorylation of FRS2 Y196 and *ERK1/2* T202/Y204) in vitro and vivo. DGY-09-192 can be used for the study of FGFR-driven cancers. (Pink: FGFR1/2 ligand (HY-160013), Blue: VHL Ligand (HY-112078), Black: Linker (HY-W020017)) ^[1].

HY-10337

Brivanib 2 Publications Verification BMS-540215	VEGFR Autophagy	Cancer
Brivanib (BMS-540215) is an ATP-competitive inhibitor against VEGFR2 with an IC₅₀ of 25 nM, and has moderate potency against VEGFR-1 and FGFR-1, but >240-fold against PDGFR-β ^[1].

HY-N7715

Ferulic acid acyl-β-D-glucoside Ferulic acid glucoside; Feruloyl glucose ester	Drug Metabolite	Others
Ferulic acid acyl-β-D-glucoside (Ferulic acid glucoside) is a metabolite of Ferulic Acid (HY-N0060). Ferulic acid acyl-β-D-glucoside can be isolated from flaxseed extract. Ferulic acid is a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor with IC₅₀ values of 3.78 and 12.5 μM for *FGFR1* and *FGFR2*, respectively ^[1] .

HY-13311A

Infigratinib phosphate 45+ Cited Publications BGJ-398 phosphate; NVP-BGJ398 phosphate	FGFR	Cancer
Infigratinib phosphate (BGJ-398 phosphate; NVP-BGJ398 phosphate) is a potent inhibitor of the *FGFR* family with IC₅₀ of 0.9 nM, 1.4 nM, 1 nM, and 60 nM for *FGFR1, FGFR2, FGFR3, and FGFR4*, respectively.

HY-148779

FGFR3-IN-5	FGFR	Cancer
FGFR3-IN-5 is a potent and selective *FGFR3* inhibitor with IC₅₀ values of 3, 44, and 289 nM for FGFR3, FGFR2, and FGFR1, respectively. FGFR3-IN-5 can be used in research of cancer ^[1].

HY-100315

XL 999 Tyrosine kinase-IN-1	VEGFR PDGFR FGFR	Cardiovascular Disease Cancer
XL999 is a multi-target tyrosine kinase inhibitor. XL999 has IC₅₀ values for KDR, *Flt-1, FGFR1* and PDGFRα of 4 nM, 20 nM, 4 nM and 2 nM, respectively. XL999 can be used in the research of cancer ^[1].

HY-156019

FGFR1 inhibitor-10	FGFR	Cancer
FGFR1 inhibitor-10 (Compound 4i) is an *FGFR1* inhibitor (IC₅₀: 28 nM). FGFR1 inhibitor-10 inhibits the phosphorylation of FGFR1. FGFR1 inhibitor-10 has anti-angiogenic, anti-invasion activity, and anti-tumor effect ^[1].

HY-162153

CYY292	FGFR	Cancer
CYY292 is an *FGFR1* inhibitor that specifically targets the FGFR1/AKT/Snail pathway in GBM cells. CYY292 dose-dependently inhibits cancer cell proliferation, epithelial-mesenchymal transition, stemness, invasion, and migration in vitro ^[1].

HY-15599

SSR128129E 1 Publications Verification SSR	FGFR	Cancer
SSR128129E is an orally available and allosteric *FGFR* inhibitor with an IC₅₀ of 1.9 μM for FGFR1.

HY-12965

S49076 1 Publications Verification	FGFR c-Met/HGFR	Cancer
S49076 is a novel, potent inhibitor of MET, AXL/MER, and *FGFR1/2/3* with IC₅₀ values below 20 nM.

HY-10336

Brivanib (alaninate) 2 Publications Verification BMS-582664	VEGFR Autophagy	Cancer
Brivanib alaninate (BMS-582664) is an ATP-competitive inhibitor against VEGFR2 with an IC₅₀ of 25 nM; has moderate potency against VEGFR-1 and FGFR-1, but more than 240-fold against PDGFRβ ^[1].

HY-136605

DGY-06-116 2 Publications Verification	Src	Cancer
DGY-06-116 is an irreversible covalent, selective Src inhibitor with an IC₅₀ of 3nM. DGY-06-116 inhibits FGFR1 with an IC₅₀ of 8340 nM ^[1].

HY-176862

TCB-32	FGFR ERK	Inflammation/Immunology
TCB-32 (Compound I-1) is a *FGFR1* agonist with an EC₅₀ of 0.88  μM. TCB-32 significantly increases cell proliferation through activating FGFR1 signaling pathway as bFGF and its downstream *ERK1/2* with excellent thermal stability. TCB-32 can replace bFGF in serum-free cell culture media. TCB-32 can be used for tissue repair and wound healing related diseases like psoriasis and eczema research ^[1] .

HY-15813

FIIN-1 FGFR irreversible inhibitor-1	FGFR	Cancer
FIIN-1 is a potent, irreversible, selective *FGFR* inhibitor. FIIN-1 binds to *FGFR1/2/3/4* and *Flt1/4* with K_ds of 2.8/6.9/5.4/120 nM and 32/120 nM respectively. The biochemical IC₅₀s of FIIN-1 are 9.2, 6.2, 11.9, and 189 nM against FGFR1/2/3/4, respectively ^[1].

HY-114311

FGFR1/DDR2 inhibitor 1 2 Publications Verification	FGFR Discoidin Domain Receptor	Cancer
FGFR1/DDR2 inhibitor 1 is an orally active inhibitor of fibroblast growth factor receptor 1 (FGFR1) and discoindin domain receptor 2 (DDR2), with IC₅₀ values of 31.1 nM and 3.2 nM, respectively. Antitumor activity ^[1].

HY-RS04911

FGFR1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA) FGFR	Others
FGFR1 Human Pre-designed siRNA Set A contains three designed siRNAs for FGFR1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

FGFR1 Human Pre-designed siRNA Set A FGFR1 Human Pre-designed siRNA Set A

HY-W007587

9-Bromononanoic acid	PROTAC Linkers	Cancer
9-Bromononanoic acid is a PROTAC linker. 9-Bromononanoic acid can be used in synthesis PROTAC FGFR1 degrader-1 (HY-170869) ^[1].

HY-163705

BR-cpd7	PROTACs FGFR	Cancer
BR-cpd7 is a PROTAC degrader for fibroblast growth factor receptor *FGFR1/2* with DC₅₀ of 10 nM. BR-cpd7 arrests cell cycle, inhibits proliferations of FGFR1/2 aberrant activated tumor cells. (Pink: ligand for target protein FGFR-IN-12 (HY-160013); Black: linker; Blue: ligand for E3 ligase Thalidomide-NH-CH2-COOH (HY-131717)) ^[1]

HY-145231

FGFR2-IN-2	FGFR	Cancer
FGFR2-IN-2 (Compound 38) is a selective *FGFR2* inhibitor with IC₅₀s of 389, 29, and 758 nM for FGFR1, FGFR2, and FGFR3, respectively ^[1].

HY-18603

FIIN-3	EGFR FGFR	Cancer
FIIN-3 is an irreversible inhibitor of *FGFR* with an IC₅₀ of 13.1, 21, 31.4, and 35.3 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively.

HY-170869

*PROTAC FGFR1* degrader-1**	PROTACs FGFR	Cancer
PROTAC FGFR1 degrader-1 (compound S2H) is a PROTAC degrader targeting FGFR1, with IC₅₀=26.81 nM and DC₅₀=39.78 nM in KG1a cells. PROTAC FGFR1 degrader-1 is composed of CRBN-type E3 ligase ligand (blue part) Pomalidomide (HY-10984), target protein ligand (red part) FGFR1 ligand-1 (HY-170871), and PROTAC linker (black part) 9-Bromononanoic acid (HY-W007587), in which the E3 ligase ligand and linker form a conjugate E3 Ligase Ligand-linker Conjugate 164 (HY-170870) ^[1].

HY-RS04913

Fgfr1 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA) FGFR	Others
Fgfr1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Fgfr1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Fgfr1 Rat Pre-designed siRNA Set A Fgfr1 Rat Pre-designed siRNA Set A

HY-161995

FGFR1/VEGFR2-IN-2	Apoptosis Necroptosis FGFR VEGFR PDGFR	Cancer
FGFR1/VEGFR2-IN-2 (compound 6l) is a *VEGFR2/FGFR1* dual inhibitor. The IC₅₀ values for VEGFR2 and *FGFR1* are 0.025 µM and 0.026 µM respectively, and for EGFR and PDGFR-β, the IC₅₀ values are 0.106 µM and 0.077 µM. FGFR1/VEGFR2-IN-2 showes significant anti-cancer activity (GI=60.38%) on NCI-60 cell line, with an IC₅₀ of 8.51 µM in T-47D cell line and anti-migration. FGFR1/VEGFR2-IN-2 acts to arrest cells in the G1 phase and promote apoptosis and necrosis; the IC₅₀ for MCF-7 cell line exceeds 100 µM, and the IC₅₀ for MDA-MB-231 is 69.17 µM, non-toxic to normal cells ^[1].

HY-RS04912

Fgfr1 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA) FGFR	Others
Fgfr1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Fgfr1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Fgfr1 Mouse Pre-designed siRNA Set A Fgfr1 Mouse Pre-designed siRNA Set A

HY-149488

FGFR1 inhibitor-9	FGFR	Cancer
FGFR1 inhibitor-9 (Compound 7) is an *FGFR1* inhibitor (IC₅₀s: 0.85 nM). FGFR1 inhibitor-9 binds to the ATP-binding pocket of FGFR1. FGFR1 inhibitor-9 has anticancer activity ^[1].

HY-149487

FGFR1 inhibitor-8	FGFR	Cancer
FGFR1 inhibitor-8 (Compound 9) is a *FGFR1* inhibitor (IC₅₀s: 0.5 nM). FGFR1 inhibitor-8 binds to the ATP-binding pocket of FGFR1. FGFR1 inhibitor-8 has anticancer activity ^[1].

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0060

Ferulic acid Maximum Cited Publications 16 Publications Verification Coniferic acid	Structural Classification Classification of Application Fields Plants Endogenous metabolite Human Gut Microbiota Metabolites Monophenols other families Simple Phenylpropanols Sunscreen Phenols Phenylpropanoids Cosmetic Research Disease Research Fields Source Classification Cancer	FGFR Endogenous Metabolite
Ferulic acid is a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor with IC₅₀s of 3.78 and 12.5 μM for *FGFR1* and *FGFR2*, respectively.

HY-N0060A

Ferulic acid sodium Maximum Cited Publications 16 Publications Verification Coniferic acid sodium	Structural Classification Monophenols other families Classification of Application Fields Simple Phenylpropanols Phenols Phenylpropanoids Plants Endogenous metabolite Disease Research Fields Source Classification Cancer	FGFR Endogenous Metabolite Reactive Oxygen Species (ROS)
Ferulic acid sodium is a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor with IC₅₀s of 3.78 and 12.5 μM for *FGFR1* and *FGFR2*, respectively.

HY-N0060R

Ferulic acid (Standard) 1 Publications Verification Coniferic acid (Standard)	Structural Classification Human Gut Microbiota Metabolites Monophenols other families Simple Phenylpropanols Phenols Phenylpropanoids Plants Endogenous metabolite Source Classification	Reference Standards FGFR Endogenous Metabolite
Ferulic acid (Standard) is the analytical standard of Ferulic acid. This product is intended for research and analytical applications. Ferulic acid is a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor with IC50s of 3.78 and 12.5 μM for FGFR1 and FGFR2, respectively.

HY-N7715

Ferulic acid acyl-β-D-glucoside Ferulic acid glucoside; Feruloyl glucose ester	Structural Classification Monophenols Classification of Application Fields Simple Phenylpropanols Rosaceae Other Diseases Phenols Phenylpropanoids Plants Aruncus sylvester Kostel. Disease Research Fields Source Classification	Drug Metabolite
Ferulic acid acyl-β-D-glucoside (Ferulic acid glucoside) is a metabolite of Ferulic Acid (HY-N0060). Ferulic acid acyl-β-D-glucoside can be isolated from flaxseed extract. Ferulic acid is a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor with IC₅₀ values of 3.78 and 12.5 μM for *FGFR1* and *FGFR2*, respectively ^[1] .

HY-N5112A

β,β-Dimethylacrylalkannin 3 Publications Verification Arnebin 1	Quinones Structural Classification other families Classification of Application Fields Other Diseases Plants Naphthalene Quinones Pteris livida Mett. Disease Research Fields	FGFR Necroptosis Apoptosis CDK JNK
β,β-Dimethylacrylalkannin (Arnebin 1) is an orally active *FGFR1* inhibitor (IC₅₀=2.5 μM) and the main active component of Lithospermum erythrorhizon. β,β-Dimethylacrylalkannin blocks downstream signaling by binding to the ATP pocket of FGFR1, and regulates the *CDK1/Cdc25C* pathway and ROS-JNK axis, thereby inducing G2/M phase arrest, necrosis and apoptosis in cancer cells, and inhibiting tumor proliferation. β,β-Dimethylacrylalkannin also acts as a colistin adjuvant to disrupt the cell membrane of Gram-negative bacteria. β,β-Dimethylacrylalkannin exhibits significant tumor-inhibitory effects with no obvious toxicity in PDX models, but chronic exposure to high doses may alter the relative lung/liver weights of rats, while acute exposure to high doses causes responses such as reduced motor activity. β,β-Dimethylacrylalkannin finds wide application in studies related to hepatocellular carcinoma, colorectal cancer, colistin-resistant bacterial infections, hepatitis and psoriasis ^[1] .

HY-W011873R

Palmitoleic acid (Standard)	Structural Classification Human Gut Microbiota Metabolites Microorganisms Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite
Pazopanib (Hydrochloride) (Standard) is the analytical standard of Pazopanib (Hydrochloride). This product is intended for research and analytical applications. Pazopanib Hydrochloride (GW786034 Hydrochloride) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with an IC50 of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.

Cat. No.	Product Name	Chemical Structure

HY-50904S2

Nintedanib-d8
Nintedanib-d₈ is deuterium labeled Nintedanib. Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.

HY-10981S

Lenvatinib-d4
Lenvatinib-d₄ is the deuterium labeled Lenvatinib. Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities ^[1] .

HY-12047S

Ponatinib-d8
Ponatinib-d₈ (AP24534-d₈) is a deuterium labeled Ponatinib. Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively.

HY-10208S

Pazopanib-d6
Pazopanib-d₆ is the deuterium labeled Pazopanib. Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with IC50s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.

HY-50904S1

Nintedanib-13C,d3
Nintedanib- ¹³C,d₃ is the ¹³C- and deuterium labeled Nintedanib. Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.

HY-151903S

FGFR2/3-IN-1
FGFR2/3-IN-1 is a potent and selective FGFR2 and FGFR3 (FGFR) inhibitor with IC₅₀s of 1 nM and 0.5 nM, respectively. FGFR2/3-IN-1 displays >40-fold selectivity over FGFR1/FGFR4 and other kinome. FGFR2/3-IN-1 also inhibits FGFR3 V555L and V555M mutants with IC₅₀s of 2.7 nM and 6.1 nM, respectively ^[1].

HY-50904S

Nintedanib-d3
Nintedanib-d₃ is the deuterium labeled Nintedanib. Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.

HY-N0060S1

Ferulic acid-13C3
Ferulic acid- ¹³C₃ is the ¹³C-labeled Ferulic acid. Ferulic acid is a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor with IC50s of 3.78 and 12.5 μM for FGFR1 and FGFR2, respectively.

HY-13311S

Infigratinib-d3
Infigratinib-d3 is a deuterated analog of infigratinib. Infigratinib is an effective inhibitor of the *FGFR* family, with IC₅₀ values of 0.9 nM, 1.4 nM, 1 nM, and 60 nM for *FGFR1, FGFR2, FGFR3, and FGFR4*, respectively ^[1].

HY-10981S1

Lenvatinib-d5
Lenvatinib-d₅ is the deuterium labeled Lenvatinib. Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities ^[1] .

HY-50905S

Dovitinib-d8
Dovitinib-d₈ is the deuterium labeled Dovitinib. Dovitinib (CHIR-258) is a multi-targeted tyrosine kinase inhibitor with IC₅₀s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, FGFR1/FGFR3, VEGFR1/VEGFR2/VEGFR3 and PDGFRα/PDGFRβ, respectively ^[1] .

HY-10981S2

Lenvatinib-15N,d4
Lenvatinib- ¹⁵N,d₄ is ¹⁵N and deuterated labeled Lenvatinib (HY-10981). Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits *VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET*, shows potent antitumor activities ^[1] .

HY-W705479

Pazopanib-d3 hydrochloride
Pazopanib-d₃ (hydrochloride) (GW786034-d₃ (hydrochloride)) is deuterium labeled Pazopanib (Hydrochloride). Pazopanib Hydrochloride (GW786034 Hydrochloride) is a novel multi-target inhibitor of *VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms* with an IC₅₀ of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.

HY-10208S2

Pazopanib-d3
Pazopanib-d₃ (GW786034-d₃) is deuterium labeled Pazopanib. Pazopanib (GW786034) is a novel multi-target inhibitor of *VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms* with IC₅₀s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively ^[1].

HY-W758126

(R)-Brivanib alaninate-d4
(R)-Brivanib alaninate-d₄ is the deuterium-labeled Brivanib (alaninate) (HY-10336). Brivanib alaninate (BMS-582664) is an ATP-competitive inhibitor against VEGFR2 with an IC₅₀ of 25 nM; has moderate potency against VEGFR-1 and FGFR-1, but more than 240-fold against PDGFRβ ^[1].

HY-12009S

Pazopanib-13C,d3 hydrochloride
Pazopanib- ¹³C,d₃ (hydrochloride) is the deuterium and ¹³C labeled Pazopanib hydrochloride ^[1]. Pazopanib Hydrochloride (GW786034 Hydrochloride) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with an IC₅₀ of 10, 30, 47, 84, 74, 140 and 146 nM, respectively .

HY-10208S1

Pazopanib-13C,d3
Pazopanib- ¹³C,d₃ is the deuterium and ¹³C labeled Pazopanib ^[1]. Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with IC₅₀s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively .

HY-W754878

Pemigatinib-d6
Pemigatinib-d₆ (INCB054828-d₆) is deuterium labeled Pemigatinib. Pemigatinib (INCB054828) is an orally active, selective *FGFR* inhibitor with IC₅₀s of 0.4 nM, 0.5 nM, 1.2 nM, 30 nM for FGFR1, FGFR2, FGFR3, FGFR4, respectively. Pemigatinib has the potential for cholangiocarcinoma ^[1] .

Targets Recommended: FGFR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10407G

SU 5402	VEGFR EGFR PDGFR	Cancer
SU 5402 (GMP) is SU 5402 (HY-10407) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. SU 5402 is a potent multi-targeted receptor tyrosine kinase inhibitor with IC₅₀ of 20 nM, 30 nM, and 510 nM for VEGFR2, *FGFR1, and PDGFRβ*, respectively ^[1].

HY-10321G

PD173074	FGFR TGF-beta/Smad	Cancer
PD173074 GMP is PD173074 (HY-10321) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. PD173074 is an orally active *FGFR* inhibitor that targets the transphosphorylation of *FGFR1* and *FGFR2* and blocks the FGF signaling pathway. By reducing the phosphorylation level of SMAD2 and altering the expression of Nodal/Activin target genes, PD173074 eliminates endothelial differentiation potential, thereby inhibiting the formation of capillary-like structures. PD173074 blocks the proliferation and colony formation of tumor cells and increases intratumoral cell apoptosis. PD173074 successfully reverses FGF-2-induced chemoresistance to enhance the effect of cisplatin (HY-17394) in small cell lung cancer models. PD173074 can be applied to research related to critical limb ischemia and small cell lung cancer ^[1] .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks